General Information of Drug (ID: DM213MD)

Drug Name
M-Aminophenylboronic Acid Drug Info
Synonyms
3-Aminophenylboronic acid; 30418-59-8; 3-Aminobenzeneboronic acid; (3-aminophenyl)boronic acid; M-AMINOPHENYLBORONIC ACID; 3-aminophenyl boronic acid; m-aminophenyl boronic acid; 3-amino phenylboronic acid; CHEMBL20852; Boronic acid, (3-aminophenyl)-; MFCD00007755; 280563-63-5; (m-Aminophenyl)metaboric acid; 3-Boronoaniline; EINECS 250-189-0; zlchem 430; 3-Aminophenylboronicacid; ACMC-1CTTO; 3amino phenylboronic acid; 3aminophenyl boronic acid; AC1L3NRS; (3-aminophenyl)boranediol; 3-amino-phenylboronic acid; AC1Q51DZ
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
92269
CAS Number
CAS 30418-59-8
TTD Drug ID
DM213MD

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tazobactam DM3XNUI Appendicitis DB10 Approved [2]
Clavulanate DM2FGRT Bacteremia 1A73 Approved [3]
CAZ AVI DMPG4OM Serious infection 1H0Z Phase 3 [4]
Enmetazobactam DMZKTYJ Urinary tract infection GC08 Phase 3 [5]
Vaborbactam DMDCFXJ Urinary tract infection GC08 Phase 3 [6]
MK-7655 DMLMV0O Bacterial infection 1A00-1C4Z Phase 2 [7]
CXL DM3JFZ2 Methicillin-resistant staphylococci infection 1A00-1A09 Phase 2 [8]
RASV-Sp DM4VTX6 Streptococcus infection 1B53 Phase 1 [9]
ME-1071 DMEMQ5J Bacterial infection 1A00-1C4Z Phase 1 [10]
OP-0595 DMECVP9 Bacterial infection 1A00-1C4Z Phase 1 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Staphylococcus Beta-lactamase (Stap-coc blaZ) TTHI19T BLAC_STAAU Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 Selection of TNF-alpha binding affibody molecules using a beta-lactamase protein fragment complementation assay. N Biotechnol. 2009 Nov 30;26(5):251-9.
3 A sensitive coupled HPLC/electrospray mass spectrometry assay for SPM-1 metallo-beta-lactamase inhibitors. Assay Drug Dev Technol. 2009 Apr;7(2):170-9.
4 NXL104 irreversibly inhibits the -lactamase from Mycobacterium tuberculosis. Biochemistry. 2012 Jun 5;51(22):4551-7.
5 Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum--Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother. 2020 May 21;64(6):e00180-20.
6 Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents Chemother. 2017 Oct 24;61(11):e01443-17.
7 Discovery of MK-7655, a beta-lactamase inhibitor for combination with Primaxin . Bioorg Med Chem Lett. 2014 Feb 1;24(3):780-5.
8 Beta-Lactam Antibiotics Renaissance. Antibiotics. 2014, 3(2), 193-215.
9 WO patent application no. 2010,0456,20, Recombinant bacterium capable of eliciting an immune response against streptococcus pneumoniae.
10 Multidrug-resistant Gram-negative bacterial infections: are you ready for the challenge. Curr Clin Pharmacol. 2014 Feb;9(1):27-38.
11 OP0595, a new diazabicyclooctane: mode of action as a serine -lactamase inhibitor, antibiotic and -lactam 'enhancer'. J Antimicrob Chemother. 2015 Oct;70(10):2779-86.